Trial reportDrug and alcohol review2026
Patient Experience of Withdrawal During Methadone-Buprenorphine Transfer: A Prospective Cohort Study.
Trial report in Drug and alcohol review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMethadone-to-buprenorphine transfers (MBT) are increasingly common as buprenorphine use expands. Evidence describing patient experience of withdrawal during MBT in real-world populations is limited. This study aimed to characterise withdrawal trajectories during MBT and examine whether psychosocial and clinical factors influence the severity or timing of withdrawal.
methodsThis analysis used data from a prospective, non-randomised clinical trial comparing low-dose and stop-and-start MBT techniques (n = 117). Covariates included methadone dose, duration on methadone, transfer setting, study arm, withdrawal expectancy, psychological distress, substance use and unstable housing. Withdrawal was assessed daily using the Clinical Opioid Withdrawal Scale (COWS) and Short Opiate Withdrawal Scale.
resultsNinety-four participants (80.3%) completed transfer. Withdrawal followed a consistent trajectory across the cohort, peaking around Day 5. Psychosocial and clinical characteristics-including unstable housing, substance use, psychological distress and methadone dose-were not associated with withdrawal severity or timing. Compared with stop-and-start transfer, low-dose transfer was associated with a delayed and larger increase in objective withdrawal: peak COWS occurred 2.3 days later (95% CI 0.3-4.3) and the largest one-day increase was 3.8 points higher (95% CI 0.5-7.0). DISCUSSION AND
conclusionsPatient factors often considered barriers to MBT were not associated with withdrawal severity or timing. Low-dose transfer was associated with a delayed and slightly higher withdrawal peak but did not reduce overall transfer success. These findings suggest that withdrawal during MBT follows a broadly similar trajectory across patients with differing psychosocial complexity. Planning for expected withdrawal, rather than selecting patients based on perceived complexity, may be more clinically relevant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.